{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:13:43Z","timestamp":1773904423200,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01460-8","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:27:02Z","timestamp":1773890822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of short-course blinatumomab in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Ge","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yile","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-2460","authenticated-orcid":false,"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4160","authenticated-orcid":false,"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8360-6395","authenticated-orcid":false,"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1460_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ajh.70057","volume":"100","author":"J Tinajero","year":"2025","unstructured":"Tinajero J, Nguyen K, Ngo D, Agrawal V, Shan H, Zhang J, et al. The impact of cytoreduction on blinatumomab outcomes for relapsed or refractory B-ALL with high disease burden. Am J Hematol. 2025;100:2209\u201319.","journal-title":"Am J Hematol"},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/16078454.2022.2111992","volume":"27","author":"H Zhou","year":"2022","unstructured":"Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B, et al. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. Hematology. 2022;27:917\u201327.","journal-title":"Hematology"},{"key":"1460_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"1460_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"1460_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01179-4","volume":"14","author":"EJ Jabbour","year":"2024","unstructured":"Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, et al. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024;14:203.","journal-title":"Blood Cancer J"},{"key":"1460_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"1460_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01092-w","volume":"14","author":"J Huang","year":"2024","unstructured":"Huang J, Shi B, Yu S, Xue M, Wang L, Jiang J, et al. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia\/lymphoma following allogeneic hematopoietic cell transplantation. Blood Cancer J. 2024;14:109.","journal-title":"Blood Cancer J"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"1460_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1182\/bloodadvances.2025015894","volume":"9","author":"J Ma","year":"2025","unstructured":"Ma J, Luong A, Doan A, Lin TY, Ji L, Wang CP, et al. T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia. Blood Adv. 2025;9:3689\u201393.","journal-title":"Blood Adv"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10637-024-01435-1","volume":"42","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wu X, Yang Z, Lu S, Zhang X, Yang X, et al. Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia. Invest New Drugs. 2024;42:299\u2013308.","journal-title":"Invest New Drugs"},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","volume":"17","author":"J Lu","year":"2024","unstructured":"Lu J, Qiu H, Wang Y, Zhou X, Dai H, Lu X, et al. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J Hematol Oncol. 2024;17:79.","journal-title":"J Hematol Oncol"},{"key":"1460_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01127-2","volume":"14","author":"J Lu","year":"2024","unstructured":"Lu J, Bao X, Zhou J, Li X, He Z, Ji Y, et al. Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease. Blood Cancer J. 2024;14:143.","journal-title":"Blood Cancer J"},{"key":"1460_CR14","first-page":"596","volume":"110","author":"M Algeri","year":"2025","unstructured":"Algeri M, Massa M, Pagliara D, Bertaina V, Galaverna F, Pili I, et al. Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation. Haematologica. 2025;110:596\u2013607.","journal-title":"Haematologica"},{"key":"1460_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/blood-2021-144843","volume":"138","author":"IM Van Der Sluis","year":"2021","unstructured":"Van Der Sluis IM, De Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G. A phase 2 study to test the feasibility, safety and efficacy of the addition of blinatumomab to the interfant06 backbone in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia. a collaborative study of the interfant network. Blood. 2021;138:361\u20133.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01460-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:27:04Z","timestamp":1773890824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01460-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional review boards and independent ethics committees and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"31"}}